Pfizer announced that the European Commission has approved expanding the use of Prevenar 13 to older children and adolescents aged 6 to 17 years for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae. Children in this age group who have not previously received Prevenar 13 may receive a single dose of the vaccine.

http://www.businesswire.com/news/home/20130108005435/en/Pfizer-Receives-European-Approval-Expand-Prevenar-13